Navigation Links
ESA and EC take major step forward in GMES
Date:12/19/2007

d, marine and emergency, two pilot service projects focusing on security and atmospheric composition, as well as downstream and other public GMES-related services.

The data access grant considers the EO data needs from the GMES services and covers the analysis of the services requirements, the negotiation of data access agreements with contributing missions, as well as the development and pre-operations of coordinating functions linking EO data providers with service providers.

Under the grant, ESA will coordinate the data provision activities from the EO contributing missions and will act as Data Provider for its own missions as well as its Third Party Missions.


'/>"/>

Contact: Simonetta Cheli
simonetta.cheli@esa.int
39-069-418-0350
European Space Agency
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
2. Laboratory at UI plays major role in diagnosing cancer
3. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
4. DaVita Acquires Majority Stake in HomeChoice Partners, Inc.
5. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
6. Major grant advances UWs clinical and translational research enterprise
7. Major differences revealed in how local authorities in the UK support disabled people
8. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
9. Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market
10. Ericom Provides Significant Cost-Savings for Major New York City Healthcare Organization
11. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2008)...ay 11 /PRNewswire/ -- The winners of today,s Susan...ollows:, 1st Place Overall Winners Male: ...le: Kelly Knickelbein, Pittsburgh, Pa., 19:19, 2... 16:02 Female: Anna Beck, Washington, Pa., 1...ie Ban, Pittsburgh, Pa., 16:13 Female: Jessi...
(Date:5/11/2008)...norCare Facilities, Caregivers Call for Better Car...swire-USNewswire/ -- Families visiting their,loved...in sixteen states,across the nation this Mother,s ...from quality care advocates. The effort asks famil...Director David Rubenstein to demand better,care. I...
(Date:5/10/2008)...ay 10 /PRNewswire/ -- Children,s Hospital of Pitts...ts new state-of-the-art hospital,campus., (Photo:...A001 ), When the new Children,s Hospital opens i... care nationwide. The new hospital building will,s...ment project that is,situated on a 10-acre campus....
(Date:5/9/2008)...cation Indicated for Maintenance Treatment for ADH...Eli Lilly and Company,(NYSE: LLY ) announced toda...ion (FDA) has approved Strattera(R) (atomoxetine H.../Hyperactivity Disorder (ADHD) in,children and ado...uptake,inhibitor, is the first FDA-approved non-st...
Breaking Medicine News(10 mins):Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Advocates Make Mother's Day Push for Quality Care 2Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 2Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 3Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6
...’s or KFC restaurants, across the world, have vary...an the levels of the same // food elsewhere. Accor...ew England Journal of Medicine, the researchers an...d's chicken nuggets, KFC hot wings, french fries f...
...hich is in its infancy demands a lot of funding to...ouncil of Medical Research (ICMR).// Delivering t...em cell research in India', Ganguly said there was...for such research. 'There is a huge scope but wha...
...un while men buy for comfort. Well, that is about ...healthy and comfortable// options this spring. The...s, flat shoes and wedge heels. Dr. Brodsky, orth...edical staff at Baylor University Medical Center a...
...ence inflammation. According to a German clinical ... University of Bonn, it was found that high doses ...ory molecules and appear to boost the anti-inflamm...e published in the American Journal of Clinical Nu...
Other Medicine News:Health News:High Dose Of Vitamin D3 A Boon for Patients Suffering From Heart Failure 2
(Date:5/8/2008)...he Cancer Research Alliance, an,organization compr...asking,303 million Americans to exercise their pow...fforts this Mother,s Day through Father,s Day., T..." has two key goals:,to activate Americans everywh...g together to exercise their collective power over...
(Date:5/8/2008)...FirstCall/ -- Alpharma Inc. (NYSE: ALO ),a globa...d results from,clinical trials that showed ALO-01 ...th sequestered naltrexone hydrochloride) capsules,...ng abuse liability,alongside a promising safety an...esented at the 27th Annual Scientific Session of t...
(Date:5/8/2008)...wire-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nas...tigator-sponsored,Phase I/II clinical trial of its...in combination with cytarabine in elderly patients...mia (AML) and high-risk,myelodysplastic syndromes ...ction of Ellen K. Ritchie, M.D. at The Weill-Corne...
(Date:5/8/2008)... Center Investigators to Assess BSI-201 ..., BRISBANE, Calif., May 8 /- BiPar S...se 2 clinical trial programs for its lead,product,...or clinical trial,of BSI-201 that BiPar has launch...als in breast and brain cancer., The company is e...
Breaking Medicine Technology:World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer 2Chemizon Announces Research Collaboration Expansion With Takeda 2456 1Chemizon Announces Research Collaboration Expansion With Takeda 2456 2Assay Designs 28TM 29 Announces Additions to the Leadership Team 955 1Assay Designs 28TM 29 Announces Additions to the Leadership Team 955 2Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 1Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 2Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 3Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 4Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 5Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 6Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 7Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2452 8Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care 2448 1Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care 2448 2Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care 2448 3Commercial Insurers Reimbursement Rate to New Yorks Community Health Centers Jeopardizes Care 2448 4
... Evaluable Patients Receiving Combination of,Bavit...,Tumor Response or Stable Disease - , - 75% of ... Gemcitabine , ,Achieved Objective Tumor...Patients Receiving Combination of Bavituximab Plus...ive Tumor Response - , - Trial Results Suppo...
...l Drug Being Pursued for the Treatment of Ischemic...re-FirstCall/ --,Neurobiological Technologies, Inc...alysis of data from prior clinical trials of,ancro...,investigational drug, Viprinex (ancrod), for the ...ual European Stroke Congress in,Glasgow, Scotland ...
Other Medicine Technology:Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 2Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 3Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 4Peregrine Pharmaceuticals Reports Positive Top-Line Results in,Bavituximab Combination Therapy Trial in Advanced Cancer Patients 5Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 2Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 3Presentations at 2007 European Stroke Congress Highlights New,Direction for Viprinex (ancrod) 4
Designated most popular model or size. 3 mm tip.
Octagonal handle. 3 mm wide.
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle.
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1.
Medicine Products: